Loading
A phase 2 trial of Botensilimab in colorectal cancer, run by Stingray Therapeutics, now recruiting.
Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) is a phase 2 interventional study registered as NCT06589440 by Stingray Therapeutics, with 70 participants planned, started 2024-11-20 and due to reach its primary completion in 2027-07-31. Interventions recorded: SR-8541A. Conditions listed: Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Botensilimab, Colorectal cancer.
Shares Botensilimab, Colorectal cancer.
Shares Botensilimab, Colorectal cancer.
Shares Botensilimab, Colorectal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/